News
EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment
Earnings Call Insights: EyePoint Pharmaceuticals (EYPT) Q2 2025 Management View Jay S. Duker, President and CEO, hig…
August 06, 2025